存储血样中的“化石记录”让科学家追溯白血病数十年前的演变
'Fossil record' in stored blood samples lets scientists trace leukemia back decades before diagnosis
研究人员通过分析存储的血样,发现急性髓系白血病(AML)在诊断前数十年就开始发展,其中两组女性中有三分之二的病例在20岁前就已携带致癌突变。研究揭示了这些突变的演变过程,有助于早期预测和预防AML。
研究通过分析存储的血样揭示了急性髓系白血病(AML)的早期演变过程,为早期预防提供了新线索。
Scientists have reconstructed how acute myeloid leukemia (AML) develops over the decades before diagnosis, showing that in two-thirds of cases the first cancer-driving mutation had been acquired before the age of 20—more than 50 years before diagnosis.
The discovery could help predict whether an individual will develop the disease years—or even decades—before symptoms arise, raising the possibility of preventing the disease before it develops.
In research published in Nature, a team at the University of Cambridge and UCL used blood samples collected annually, some dating back 15 years before diagnosis, as a "fossil record" of the disease's development, tracing it step by step.
Using ultrasensitive DNA sequencing and mathematical modeling, they estimated when each mutation arose and how quickly the affected cells multiplied and competed with other blood cells in the years prior to AML diagnosis.
AML is an aggressive blood cancer affecting around 2,700 people in the U.K. each year. Only around one in six survive five years after diagnosis. Many healthy older people carry blood cells with mutations also found in leukemia, a condition known as clonal hematopoiesis, but only a small proportion develop AML. What has not been clear is why, because the process has never been tracked year by year in the run-up to diagnosis.
Decades of growth, then rapid expansion
The researchers used samples from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), in which around 50,000 women gave a blood sample every year for up to 11 years. The team studied 47 women who later developed AML, at an average age of 72, alongside matched samples from 46 women who stayed blood cancer-free.
This first mutation, acquired before age 20 in two-thirds of the women who developed AML, was followed by decades of slow growth—cells carrying it took years to double in number. Each additional mutation increased their growth rate around two- to threefold, with cells carrying four cancer-driving mutations doubling in a matter of weeks.
The growth of these groups of cells, known as clones, proved remarkably predictable. Once a clone carrying a cancer-driving mutation was established, it expanded at a steady rate, slowing only when it ran out of room or was overtaken by a faster-growing clone. In practice, this means a clone's growth rate, measured from a few blood samples today, can be used to estimate how large that clone may become years and even decades into the future.
Dominant clones signal higher risk
In at least a third of the AML cases, a clone had come to dominate the blood years before diagnosis, a phenomenon known as a 'somatic sweep.' No such sweeps were seen in the women who remained blood cancer-free. The team confirmed the link with AML risk using UK Biobank data, finding that people with these sweeps were at greatly increased risk of developing the disease.
The findings highlight the importance of recognizing this potential warning sign, which standard genetic analysis often overlooks by mistaking these mutations for inherited variants.
Professor Jamie Blundell from the Early Cancer Institute at the University of Cambridge, who led the study, said, "Serial blood samples are a fossil record of the blood's evolution. They let us go back in time and reconstruct when each mutation arose and how fast it grew. What surprised us most is how predictable the growth of these clones is. Once a clone is established, its growth rate today tells you where it will be years, even decades, from now."
He added, "Because the growth is exponential, even modestly slowing a high-risk clone over the decade or more before diagnosis could substantially reduce the chance it becomes leukemia. This opens up strategies we can exploit to prevent these clones ever becoming leukemia."
Dr. Caroline Watson, also from the Early Cancer Institute and first author of the study, said, "As a hematologist, I've seen how suddenly AML can change someone's life. This study shows that the changes leading to AML can build over decades, with the affected cells growing in surprisingly predictable ways."
Watson is also an honorary consultant hematologist and sees patients at the Cambridge Clonal Hematopoiesis Clinic at Addenbrooke's Hospital, the first clinic focusing on leukemia prevention in Europe. She added, "At our clinic, we already assess and monitor people who carry blood-cell mutations that increase their risk of leukemia. Today's findings give us real hope of improving how we identify which of them are at greatest risk and point to a window in which prevention could one day be possible."
Professor Usha Menon, from the UCL Institute of Clinical Trials and Methodology, who led UKCTOCS, said, "UKCTOCS was designed to test screening for ovarian cancer, but the samples the participants donated are proving valuable far beyond that."
Limits and prospects for prevention
The women were diagnosed with AML between the ages of 53 and 83, and the study did not include samples taken at the time of diagnosis. In around one in five cases, expanding populations of mutated cells were not detectable until one to two years before AML diagnosis, suggesting that some cases may offer a shorter warning period.
The findings point toward opportunities for early detection and prevention. The team's modeling suggests that even a small reduction in a clone's growth rate, compounded over the 10 or more years between the second mutation and diagnosis, could substantially reduce the risk of progression to leukemia. This raises the possibility of preventive treatments that slow these cells' growth before leukemia develops.
Testing whether this can be achieved safely and effectively in people identified as high risk is the team's next step.
Publication details
Caroline Watson et al. Evolutionary dynamics in the years preceding acute myeloid leukaemia, Nature (2026). DOI: 10.1038/s41586-026-11269-x
Journal information: Nature
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: 'Fossil record' in stored blood samples lets scientists trace leukemia back decades before diagnosis (2026, November 11) retrieved 11 November 2026 from https://medicalxpress.com/news/2026-11-fossil-blood-samples-scientists-leukemia.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com